Patents by Inventor Kurt Puentener

Kurt Puentener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11021503
    Abstract: The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt of an oligonucleotide with a GalNAc cluster compound or with a salt thereof and a subsequent purification.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 1, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simon Breitler, Joerg Lill, Kurt Puentener, René Trussardi
  • Publication number: 20200407392
    Abstract: The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid derivatives of the formula I can be used in preloaded solid supports of the formula III and as that serve as suitable start material for oligonucleotide synthesis.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: KURT PUENTENER, CHRISTOPH ROSENBOHM, FILIPPO SLADOJEVICH
  • Publication number: 20200079807
    Abstract: The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt of an oligonucleotide with a GalNAc cluster compound or with a salt thereof and a subsequent purification.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 12, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Simon BREITLER, Joerg LILL, Kurt PUENTENER, René TRUSSARDI
  • Publication number: 20190106416
    Abstract: The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 11, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kurt Puentener, Michelangelo Scalone
  • Publication number: 20180029978
    Abstract: The invention relates to compounds of the formula and to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Kurt Puentener
  • Patent number: 9802886
    Abstract: The invention relates to compounds of the formula and to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 31, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Kurt Puentener
  • Publication number: 20170174725
    Abstract: Provided herein is a process for the preparation of oxytocin receptor agonists that have the potential to be used for the treatment of neurological disorders.
    Type: Application
    Filed: February 7, 2017
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Anton Cueni, Kurt Puentener, Junichi Shiina
  • Publication number: 20170057912
    Abstract: The invention relates to compounds of the formula and to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Kurt Puentener
  • Patent number: 9522874
    Abstract: The invention relates to compounds of the formula I. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: December 20, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Kurt Puentener
  • Patent number: 9505759
    Abstract: A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula wherein R1 is C1-4-alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R2 is C1-4-alkyl, C1-4-alkoxycarbonyl, halogen, phenyl which is optionally substituted with C1-4-alkyl, C1-4-alkoxy or halogen or is NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R3 is C1-4-alkyl and X is nitrogen or CH is described.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: November 29, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Serena Maria Fantasia, Kurt Puentener
  • Publication number: 20160046628
    Abstract: A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula wherein R1 is C1-4-alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R2 is C1-4-alkyl, C1-4-alkoxycarbonyl, halogen, phenyl which is optionally substituted with C1-4-alkyl, C1-4-alkoxy or halogen or is NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R3 is C1-4-alkyl and X is nitrogen or CH is described.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Serena Maria Fantasia, Kurt Puentener
  • Patent number: 9115130
    Abstract: The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof wherein R1 stands for hydrogen, a halogen, for an optionally protected hydroxyl group or for an optionally protected amino group and R2 is hydrogen or a halogen. 2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: August 25, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Bjoern Bartels, Serena Maria Fantasia, Alexander Flohr, Kurt Puentener, Shaoning Wang
  • Publication number: 20150073173
    Abstract: The invention relates to compounds of the formula to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: Kurt Puentener
  • Publication number: 20150025249
    Abstract: The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 22, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kurt Puentener, Michelangelo Scalone
  • Publication number: 20140350259
    Abstract: The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof wherein R1 stands for hydrogen, a halogen, for an optionally protected hydroxyl group or for an optionally protected amino group and R2 is hydrogen or a halogen. 2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Bjoern Bartels, Serena Maria Fantasia, Alexander Flohr, Kurt Puentener, Shaoning Wang
  • Patent number: 8450496
    Abstract: The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: May 28, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kurt Puentener, Michelangelo Scalone
  • Patent number: 8344161
    Abstract: The invention relates to a novel process for the preparation of (3S,4S)- or (3R,4R)-1-benzyl-4-(halogen-aryl)-pyrrolidine-3-carboxylic acids of formula I or salts thereof, wherein X and Y are each independently hydrogen or a halogen atom, with the proviso that at least one of X or Y is a halogen atom. The compounds of formula I are useful as starting materials or intermediates for the preparation of pharmaceutically active compounds, especially for compounds, which are useful for the treatment of central nervous system disorders.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: January 1, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fabienne Hoffmann-Emery, Kurt Puentener, Hasane Ratni
  • Patent number: 8288534
    Abstract: The invention relates to a novel process for the preparation of Ruthenium metathesis catalysts of the formula Ruthenium metathesis catalysts have been widely applied in the synthesis of macrocyclic drug compounds.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: October 16, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Angelino Doppiu, Ralf Karch, Kurt Puentener, Andreas Rivas-Nass, Michelangelo Scalone, Roland Winde, Eileen Woerner
  • Patent number: 7939668
    Abstract: The invention relates to novel metathesis catalysts of the formula a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula VII which have the potential to be useful as HCV protease inhibitors.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: May 10, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Kurt Puentener, Michelangelo Scalone
  • Patent number: 7910728
    Abstract: The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: March 22, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Stefan Hildbrand, Kurt Puentener, Michelangelo Scalone